What Type of Insulin Is Used for Insulin Pump Therapy?

Insulin pumps use rapid-acting insulin analogs, not the long-acting or intermediate-acting formulations that many people associate with diabetes treatment. The three standard options are insulin lispro (Humalog), insulin aspart (NovoLog/NovoRapid), and insulin glulisine (Apidrin), all of which begin working within about 15 minutes of delivery. Newer ultra-rapid versions of lispro and aspart have entered the picture in recent years, and the choice between all of these is less straightforward than it might seem.

Why Only Rapid-Acting Insulin Works in a Pump

An insulin pump delivers tiny pulses of insulin around the clock through a small catheter sitting just under the skin. This continuous trickle of rapid-acting insulin replaces the long-acting or intermediate-acting injection that a person on multiple daily injections would take once or twice a day for background coverage. At mealtimes, the pump delivers a larger burst of the same rapid-acting insulin to handle the incoming carbohydrates. Because one formulation handles both jobs, the pump eliminates the need for separate basal and bolus insulins entirely.¹

This setup depends on the insulin acting fast and clearing quickly. If a long-acting insulin were loaded into the reservoir instead, the pump could not fine-tune delivery hour by hour, because the insulin would pool under the skin and release slowly over many hours on its own schedule. The whole advantage of pump therapy is precision: you can program different basal rates for different times of day, suspend delivery during exercise, or ramp it up during illness. That flexibility only works with an insulin that responds on a short timeline.

The Three Standard Rapid-Acting Analogs

Lispro, aspart, and glulisine have been the workhorses of pump therapy for more than two decades. All three are genetically engineered tweaks of human insulin that prevent the molecules from clumping together as tightly, which speeds absorption from the tissue under the skin. In head-to-head comparisons, their absorption rates and their effects on blood sugar control are similar.² Glulisine showed a slightly faster onset in some studies, but that advantage faded within an hour, after which all three performed alike.

Where they differ in meaningful ways is in side-effect profiles during pump use. Clinical trials found that insulin aspart was associated with fewer episodes of low blood sugar compared with both human regular insulin and insulin lispro in people with type 1 diabetes using pumps.³ That difference matters because hypoglycemia is one of the scariest complications of tight blood sugar management, and pump users tend to aim for tighter targets than people on injections.

In practice, though, the choice between these three often comes down to insurance formulary coverage, personal preference, and how well a particular insulin behaves in a specific pump model. Some people notice that one analog causes less irritation at their infusion site than another, or that their blood sugar responds more predictably to one versus the others. These individual differences are real but hard to predict in advance.

Stability Inside the Reservoir

Insulin sitting in a plastic reservoir strapped to your body faces a hostile environment: body heat, mechanical vibration from movement, and days of exposure before the cartridge is swapped out. If the insulin degrades or clumps together, it loses potency, and worse, it can clog the tiny tubing that connects the pump to the infusion site. An occlusion like that means insulin delivery stops silently until the pump’s alarm triggers, which can lead to dangerously high blood sugar.

Fortunately, the standard rapid-acting analogs hold up well under these conditions. Insulin lispro tested in a MiniMed Paradigm pump maintained its potency for a full 14 days under standard use conditions, with no visible clumping and no occlusion alarms.⁴ Insulin aspart products, including a biosimilar version, were similarly stable in Medtronic pumps for up to 13 days under stress conditions that included elevated temperature and continuous vibration, with no occlusion events.⁵

That said, there is a genuine tension built into rapid-acting insulin design. The same molecular changes that make these analogs absorb quickly also make them inherently less stable in solution over time. They are more prone to a process called fibrillation, where molecules misfold and aggregate into clumps, especially at higher temperatures.⁶ This is why pump manufacturers recommend changing the reservoir and infusion set every two to three days, even though the insulin itself may test fine for longer periods in laboratory conditions. Real-world heat exposure on a summer day or during a beach vacation accelerates degradation in ways that controlled lab tests do not fully capture.

Ultra-Rapid Analogs and What They Add

Two newer formulations have joined the pump-compatible lineup: faster-acting insulin aspart (brand name Fiasp) and ultra-rapid insulin lispro (brand name Lyumjev). These are not entirely new insulin molecules. They are the same aspart and lispro backbones reformulated with additional excipients that speed their absorption once injected. The goal is to better match the speed of a healthy pancreas, which releases insulin almost instantly when food arrives.

A meta-analysis pooling nine studies with over 1,100 participants found that ultra-rapid insulins used in pumps modestly improved time in the target glucose range compared with standard rapid-acting analogs, with a mean difference of about 1.1 percentage points. They also reduced time spent in hypoglycemia and lowered blood sugar spikes after meals, with post-meal glucose dropping roughly 12 mg/dL at one hour and about 18 mg/dL at two hours.⁷

The catch is that ultra-rapid formulations come with a higher rate of infusion set problems. That same meta-analysis found that people using ultra-rapid insulin had about 60% higher odds of needing an unplanned infusion set change.⁷ It is not entirely clear whether the added excipients irritate the tissue at the infusion site or cause more catheter occlusions, but the effect is consistent enough that people who switch to ultra-rapid insulin in their pump should be prepared for more frequent set changes.

Fiasp Versus Lyumjev in Pumps

Although these two products are often discussed interchangeably as “ultra-rapid insulins,” they do not perform identically when used in pump systems. A detailed analysis of postprandial glucose data from two randomized crossover trials in adults with type 1 diabetes using a hybrid closed-loop system found clear differences. Lyumjev, compared with standard insulin lispro, significantly reduced post-meal blood sugar spikes after breakfast and dinner, with time in target range improving by roughly 6 to 7 percentage points during the four hours after those meals. Fiasp, by contrast, showed no significant improvement over standard insulin aspart for post-meal glucose control at any meal.⁸

This does not mean Fiasp is useless in a pump. Its benefits may appear in contexts other than post-meal spikes, and some users do report subjective improvements. But if the primary motivation for switching to an ultra-rapid insulin is better after-meal control, the evidence so far tilts toward Lyumjev as the stronger performer in closed-loop systems.

Ultra-Rapid Insulin and Exercise

One area where ultra-rapid insulin lispro may offer a distinct practical advantage is during physical activity. Exercise increases blood flow to muscle and skin, which can accelerate insulin absorption from the infusion site. The result is that insulin already deposited under the skin gets pulled into the bloodstream faster than expected, raising the risk of low blood sugar during or shortly after a workout.

A study comparing ultra-rapid lispro to standard lispro during exercise in adults with type 1 diabetes on open-loop pumps found that glucose dropped less steeply during exercise with the ultra-rapid version. This may seem counterintuitive — faster insulin dropping glucose less — but the explanation lies in the fact that ultra-rapid lispro clears from the infusion site sooner, leaving less of a lingering depot to be swept up by exercise-induced blood flow. Hypoglycemia during exercise occurred in about 6% of sessions with ultra-rapid lispro compared with 16% with standard lispro.⁹ After exercise, the faster absorption of ultra-rapid lispro also helped manage the post-workout meal more effectively.

Automated Insulin Delivery Systems

The latest generation of insulin pumps does not just deliver programmed rates — it adjusts insulin delivery automatically based on continuous glucose monitor readings. These automated insulin delivery (AID) or “closed-loop” systems are increasingly common, and the insulin choice matters because the algorithm is making dosing decisions every few minutes. A faster-acting insulin gives the algorithm more responsive tools to work with.

A meta-analysis of randomized controlled trials comparing ultra-rapid insulin analogs to standard rapid-acting analogs in closed-loop systems found that the ultra-rapid versions significantly reduced glycemic variability (by about 0.78 percentage points in the coefficient of variation) and cut time spent below 70 mg/dL, a marker of hypoglycemia.¹⁰ Less variability and less hypoglycemia together is a meaningful combination, since most attempts to tighten control tend to increase hypoglycemia risk.

One of the most compelling potential use cases for ultra-rapid insulin in automated systems is handling missed meal boluses. If you forget to bolus before eating (something every pump user does occasionally), the closed-loop algorithm has to detect the rising glucose and catch up using correction doses alone. A randomized crossover study simulating exactly this scenario found that ultra-rapid lispro led to roughly 49% time in range compared with about 40% for standard lispro, though the difference did not quite reach statistical significance in this small study.¹¹ The trend is suggestive: when the algorithm is doing all the work without a manual bolus to help, faster insulin gives it a better shot at keeping glucose in range.

Biosimilar Insulins in Pumps

As patents on the original rapid-acting analogs expire, biosimilar versions are entering the market at lower cost. A natural question is whether these biosimilars perform as well as the originals in pump systems, which make more demanding stability and delivery requirements than a simple injection.

A randomized clinical trial compared a biosimilar insulin aspart (SAR341402) head-to-head against the originator NovoLog in adults with type 1 diabetes using pumps. The rate of infusion set occlusions, the frequency of unexplained hyperglycemia, and the overall safety profile were similar between the two products.¹² Separate stability testing confirmed that the biosimilar maintained its chemical integrity in pump reservoirs for up to 13 days without producing unwanted clumps or particles.⁵ For pump users whose insurance favors a biosimilar, this is reassuring.

Concentrated Insulin for Severe Insulin Resistance

Standard pump insulin comes in a concentration of 100 units per milliliter (U-100). For most people with type 1 diabetes and many with type 2, this works fine. But some individuals with severe insulin resistance need several hundred units of insulin per day, and a U-100 reservoir simply cannot hold enough to last more than a day. This is where concentrated U-500 regular insulin enters the picture.

U-500 is five times more concentrated than standard insulin, meaning a pump reservoir can hold five times the effective dose. It is not a rapid-acting analog — it is regular human insulin — and its action profile is slower, peaking later and lasting longer. This makes pump programming trickier, because the absorption curve does not match what the pump’s software expects.

Despite being off-label for pump use, small studies have shown promising results. A prospective trial using U-500 delivered by an Omnipod pump in people with type 2 diabetes and severe insulin resistance found it to be both safe and effective.¹³ An earlier study reported that after three months on U-500 via pump, participants saw their HbA1c drop by an average of 1.14 percentage points, with no serious hypoglycemia events, and all patients preferred the pump over their previous regimens.¹⁴ Early experience with U-500 in automated insulin delivery systems has also been cautiously positive, though the data remains limited to very small cohorts.¹⁵

Diluted Insulin for Very Young Children

At the opposite end of the spectrum, infants and toddlers with type 1 diabetes face the problem of needing incredibly tiny insulin doses. A baby might need fractions of a unit per hour as a basal rate, and pump motors are not designed to deliver such minuscule volumes accurately. The solution some clinics have adopted is diluting U-100 insulin down to U-10 (one-tenth concentration), which allows the pump to deliver ten times the fluid volume for the same dose, improving mechanical accuracy.

Clinical experience using diluted insulin in automated delivery systems for very young children has shown benefits including fewer hypoglycemic episodes and fewer technical malfunctions compared with standard-concentration insulin in this age group.¹⁶ One study found that switching toddlers to diluted insulin led to a three-fold reduction in nighttime hypoglycemia, along with roughly an extra 1.5 hours per day spent in the target glucose range.¹⁷ This is not a commercially available product — the dilution is typically done by a pharmacy or the family under clinical guidance — but it illustrates how the “right” insulin for a pump sometimes means modifying the standard formulation to fit the patient.

Insulin Choice During Pregnancy

Pregnant individuals with type 1 diabetes or gestational diabetes who use a pump have the same rapid-acting options available to them, but the safety profile takes on extra weight when fetal health is at stake. A systematic review and meta-analysis examining insulin lispro and insulin aspart in pregnancy found both to be safe and effective for mother and fetus, with glycemic control at least as good as with regular human insulin.¹⁸ Insulin aspart has the longest track record in pregnancy studies, which is why some endocrinologists default to it for pregnant pump users. The ultra-rapid formulations have less pregnancy-specific data so far, and most clinicians remain cautious about using them until more evidence accumulates.

Intraperitoneal Pumps and Portal Delivery

A small but important niche in pump therapy involves implanted pumps that deliver insulin directly into the abdominal cavity rather than under the skin. These intraperitoneal pumps are used mainly in Europe for people with type 1 diabetes who have unpredictable subcutaneous insulin absorption or severe insulin resistance. The insulin travels through the peritoneal membrane and enters the portal venous system — the same route that insulin from a healthy pancreas takes — which can lead to more predictable glucose profiles, especially after meals.¹⁹

These devices use a buffered regular human insulin formulation specifically designed for intraperitoneal delivery, not the rapid-acting analogs used in subcutaneous pumps. The peritoneal route absorbs insulin differently than subcutaneous tissue, and the regular insulin formulation has been optimized over decades for the unique demands of an implanted reservoir that may sit at body temperature for weeks. Intraperitoneal pumps remain rare and are largely restricted to specialized centers, but they represent a fundamentally different approach to the question of which insulin belongs in a pump — one where the delivery route, not just the molecule, dictates the answer.

The Push for Even Faster Formulations

Even the current ultra-rapid analogs are slower than endogenous insulin secretion from a healthy pancreas, which enters the bloodstream almost instantly. Researchers are working on formulation strategies to close that gap further. One approach involves stripping away the zinc and preservatives that standard insulin formulations rely on for shelf stability and replacing them with alternative stabilizers. A recent study demonstrated that removing zinc and the preservative metacresol from an insulin lispro formulation, and substituting phenoxyethanol and a polymer-based stabilizer, could produce a mostly monomeric insulin that absorbs even faster than current ultra-rapid versions while maintaining acceptable stability under stress conditions.²⁰

Whether these experimental formulations make it to commercial pump cartridges depends on solving the same stability-versus-speed tradeoff that has constrained every rapid-acting insulin to date. The faster insulin molecules separate for absorption, the more vulnerable they become to degradation in a warm reservoir bouncing around on someone’s hip. For now, the practical landscape remains lispro, aspart, and glulisine as the standard choices, with Fiasp and Lyumjev as ultra-rapid alternatives that offer incremental improvements alongside a few practical trade-offs.